Parabilis Medicines sets biotech record with $670m IPO
Parabilis’ US listing means the biotech IPO record has been broken twice in as many months as public listings continue hot streak.
Therapy Area
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
ASCO26: In vivo oncology approaches continue to show promise
Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026
ATS 2026: Insmed shines in bronchiectasis with spotlight on Brinsupri
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
